A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
一项针对复发/转移性头颈部鳞状细胞癌患者的莫那利单抗和度伐利尤单抗的 II 期研究：EORTC-HNCG-1559 试验 I2 队列的结果（UPSTREAM）
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104554
Galot, R; Le Tourneau, C; Licitra, L; Guigay, J; Kong, A; Tinhofer, I; Even, C; Daste, A; Henry, S; Borel, C; Abdeddaim, C; Seront, E; Prevost, J B; Rutten, A; Saada-Bouzid, E; Rolland, F; Bonomo, P; Rasschaert, M; Dirix, L; Olungu, C; Tsechilidou, K; Govaerts, A S; Fortpied, C; Joaquim, A; Machiels, J P
